Rationale Central CB1 cannabinoid receptors regulate anxiety-like and appetitive consummatory behaviors. Pharmacological antagonism/inverse-agonism of CB1 receptors increases anxiety and decreases appetitive behaviors; however, neither well-defined dose nor context dependence of these effects has been simultaneously assessed in one behavioral assay. Objectives We sought to determine the context and dose dependence of the effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in a model that allowed for simultaneous detection of anxiety-like and consummatory-related behaviors. Methods We determined the effects of the CB1 receptor antagonist/inverse-agonist, rimonabant, in the noveltyinduced hypophagia (NIH) assay in juvenile male ICR mice. Results Rimonabant dose-dependently decreased consumption of a palatable reward solution completely independent of contextual novelty. Grooming and scratching behavior was also increased by rimonabant in a context-independent manner. In contrast, rimonabant increased feeding latency, a measure of anxiety-like behaviors, only in a novel, mildly anxiogenic context. The effects of rimonabant were specific since no effects of rimonabant on despair-like behavior were observed in the tail suspension assay. Blockade of CB2 receptors had no effect on novelty-induced increases in feeding latency or palatable food consumption. Conclusions Our findings indicate that CB1 receptor blockade decreases the hedonic value of palatable food irrespective of environmental novelty, whereas the anxiogenic-like effects are highly context-dependent. Blockade of CB2 receptors does not regulate either anxiety-like or consummatory behaviors in the NIH assay. These findings suggest that rimonabant modulates distinct and dissociable neural processes regulating anxiety and consummatory behavior to sculpt complex and context-dependent behavioral repertories.
Introduction
Endogenous cannabinoid (eCB) signaling in the central nervous system regulates diverse physiological processes; however, modulation of anxiety and appetitive behaviors are arguably the most robustly modulated by eCB signaling (Chhatwal and Ressler 2007; Di Marzo and Matias 2005; Kirkham and Tucci 2006; Maldonado et al. 2006; Riebe et al. 2012; Serrano and Parsons 2011; Vickers and Kennett 2005; Viveros et al. 2007) . With regard to anxiety-like behaviors, low doses of direct CB1 receptor agonists and indirect CB1 receptor agonists reduce unconditioned anxiety behaviors and can reduce stress-elicited neuroendocrine activation (Kathuria et al. 2003; Kinsey et al. 2010; Patel and Hillard 2006; Patel et al. 2004; Sciolino et al. 2011; Sumislawski et al. 2011) . In contrast, blockade of CB1 receptors or genetic deletion of CB1 receptors increases anxiety behaviors (Haller et al. 2002; Navarro et al. 1997; Patel and Hillard 2006) , especially under stressful conditions (Haller et al. 2004 ). These studies suggest strong contextdependent anxiogenic effects of CB1 receptor blockade on anxiety-like behaviors in rodents. These studies support the overall hypothesis that eCBs serve to buffer anxiety and stress responses in an "on demand" basis under challenging environmental conditions (Hill et al. 2010; Lutz 2009; Patel and Hillard 2008) . Consistent with this hypothesis, administration of the CB1 receptor antagonist/inverse-agonist, rimonabant, can induce anxiety symptoms in a subpopulation of human subjects (Christensen et al. 2007) .
eCBs are also prominently implicated in the modulation of appetitive behaviors (Cota et al. 2006; Pagotto et al. 2005; Parolaro et al. 2005; Thornton-Jones et al. 2005) . Pharmacological blockade of CB1 receptors reduces intake and motivation to obtain palatable food (Arnone et al. 1997; Mathes et al. 2008; Poncelet et al. 2003; Thornton-Jones et al. 2005 , 2007 . Similar effects are observed in CB1 receptor knockout mice (Poncelet et al. 2003) . Moreover, both pharmacological blockade and genetic inactivation of the CB1 receptor reduce the motivational effects of several drugs of abuse (Fattore et al. 2010; Gardner 2011; Lopez 2010; Serrano and Parsons 2011; Wiskerke et al. 2008) . Conversely, low doses of direct CB1 receptor agonists and endocannabinoids can enhance palatable food consumption and increase hedonic "liking" responses to palatable foods (Mahler et al. 2007) . Synthetic cannabinoids and cannabis use are also well known to stimulate appetite in humans (Adams and Martin 1996; Pertwee 1988) , and the use of cannabis to treat anorexia associated with malignancy and HIV disease is increasing (Johnson 1990; Nelson et al. 1994; Osei-Hyiaman 2007; Plasse et al. 1991; Struwe et al. 1993; Woolridge et al. 2005) . In contrast to the effects on anxiety, the context dependence of the role of eCB signaling in the modulation of appetitive behaviors is not well understood. Furthermore, recent studies have begun to implicate CB2 receptor signaling in reward-related processes (Onaivi et al. 2008; Xi et al. 2011) , although further investigations are required to determine the overall contribution of CB2 receptors in the regulation of appetitive behaviors.
The primary objective of the present study was to utilize a behavioral assay that allowed for the simultaneous detection of possible context-dependent dissociations between the effects of eCB signaling on anxiety-like and appetitive behaviors. Using the novelty-induced hypophagia (NIH) assay (Dulawa and Hen 2005) , we found a clear dissociation in context dependency between the effects of CB1 receptor blockade on anxiety-like and consummatory behavior with only anxietylike behaviors showing environmental context dependence.
Methods

Animals and drug administration
Juvenile male ICR mice (~6 weeks of age) were used for all experiments (Harlan, Indianapolis, IN). All mice were testnaïve and used in one experiment only. The mice were housed on a 12:12 light-dark cycle (lights on at 06:00 a.m.) with food and water available ad libitum. All studies were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by the Vanderbilt University Institutional Animal Care and Use Committee. The CB1 receptor antagonist, rimonabant, and CB2 receptor antagonist, SR144528, were gifts from the National Institute of Mental Health Drug Supply Program. Drugs or vehicle were administered by i.p. injection at a volume of 10 mL/kg in an ethanol/emulphor/saline combination in a 1:1:18 ratio. We chose three different doses of rimonabant (1, 3, or 10 mg/kg) based on previous studies demonstrating behavioral effects of rimonabant in this dose range (Patel and Hillard 2006; Wiley et al. 2005) . We chose similar doses of the CB2 receptor antagonist, SR144528, in order to provide a better comparison between the behavioral effects of CB1 and CB2 receptor blockade. Drug pretreatment times were 30 min prior to behavioral testing. All behavioral testing was performed during the inactive light phase of the mouse circadian cycle (between 10:00 a.m. and 4:00 p.m.).
Open-field locomotor assessment
To test for open-field locomotor activity in a novel environment, the mice were tested for 30 min using automated experimental chambers (27.9×27.9 cm; MED-OFA-510; MED Associates, St. Albans, Vermont) under constant illumination within a sound-attenuated room as previously described (Sumislawski et al. 2011) . All experimental chambers were cleaned in between testing with Vimoba, a chlorine dioxide solution. Activity Monitor v5.10 (MED Associates) was used to analyze open-field activity.
Novelty-induced hypophagia
Individually housed mice (7 days prior to testing) were habituated to a novel, palatable food (Ensure® Homemade Vanilla Shake) in their home cages for 30 min/day for 3 days before testing. The mice that never fed on the palatable food in their home cages within the habituation period were omitted from testing. The day after habituation ended, the mice were presented with the shake in either their home cage (under less aversive, red light illumination, 40 lux) or a novel cage (no bedding, white bottom, under more aversive, highly ambient lighting conditions, 295 lux). Red light illumination was used to reduce the aversiveness of the environmental context during home-cage testing. This lighting condition is considered to be in phase with the mouse circadian cycle. Previous studies have suggested that dim, low lighting conditions do not cause changes in behavioral assays that examine locomotor activity and stress-induced effects in ICR male mice (Betancur et al. 1994; Sykes and Henton 1982) . The shake was contained in a 50-mL clear plastic conical tube that was closed by a rubber stopper encasing a metal sipper. Throughout habituation and testing, bedding in the home cage was not changed in order to enable the mice to adapt to being individually housed. For one group of mice, we measured the latency to begin feeding and the amount consumed in two separate experimental cohorts of mice, which were combined for statistical analysis. In the second cohort of mice, we recorded in real time and analyzed the frequency and duration of drinking, grooming, and scratching over a 30-min test. We defined the mouse behaviors examined in this assay as follows: (1) latency to begin feeding (the amount of time taken to start the first feeding episode); (2) weight consumed (the amount of shake eaten by measuring the difference between the weight of the conical tube containing the shake before and after each test session); (3) drinking (licking the sipper of the conical tube that contained the shake); (4) grooming (licking the fur on the body, paws, and genitals, biting the tail, and stroking the face with paws, including the whiskers); and (5) scratching (recurring hindpaw scratching of the body, neck, ear, and face on the same side of the body) (Tallett et al. 2007a, b) .
Tail suspension test
The tail suspension test is a behavioral assay commonly used to screen antidepressant drugs. The tail suspension test was performed using four chambers under bright light conditions (175 lux) that interfaced with the Tail Suspension software (Version 3.30, MED Associates). All chambers were cleaned in between testing with Vimoba. The mice (n=10/treatment group) were individually suspended by the tail with adhesive tape from a flat stainless steel vertical bar in a white plastic cubicle. The total duration of immobility was determined from the accumulated time during which the mouse movement did not exceed a preset threshold of three for 200 ms and was recorded over a single 5-min session.
Statistical analysis NIH data were analyzed by two-way ANOVA factoring novelty and drug treatment unless noted otherwise. Effects on latency, consumption, and frequency or duration of drinking, grooming, and scratching were analyzed separately. Post hoc Sidak's multiple comparisons test was used to determine the effects of drug treatment compared to that of vehicle treatment in each condition. Open-field and tail suspension measures were analyzed by one-way ANOVA followed by Dunnett's post hoc analysis unless noted otherwise. All statistical analyses were conducted with Prism GraphPad 6 (San Diego, CA). Data are presented as mean ± SEM with p<0.05 considered significant throughout.
Results
Effects of CB1 receptor blockade on NIH
During the habituation training, the mice quickly approached and consumed the Ensure® confirming the palatability of the solution even in the absence of a food deprivation period (Dulawa and Hen 2005) . We determined the effects of 1, 3, or 10 mg/kg rimonabant on feeding latency and shake consumption during testing in either the home cage or the novel, mildly stressful cage setting. Results revealed a significant effect of drug dose (F (3, 133) =4.96, p=0.0027), testing condition (F (1, 133) =67.74, p<0.0001), and a significant interaction (F (3, 133) =4.86, p=0.0031; Fig. 1a) . Post hoc Sidak's multiple comparisons test revealed that rimonabant at 3 mg/kg (p<0.01) and 10 mg/kg (p<0.0001) significantly increased feeding latency compared to vehicle treatment in the novel testing condition only (Fig. 1a) . With respect to the effects of environmental context on feeding latency, post hoc Sidak's multiple comparisons test also revealed a significant difference between the home and novel testing condition for all rimonabant treatment groups (1 mg/kg, p < 0.01; 3 and 10 mg/kg, p<0.0001). In contrast to the effects on feeding latency, for the shake consumption data (Fig. 1b) , two-way ANOVA revealed a significant effect of drug dose (F (3, 133) = 66.84, p < 0.0001), testing condition (F (1, 133) = 12.91, p=0.0005), and drug dose × testing condition interaction (F (3, 133) =3.72, p=0.013). Post hoc Sidak's test revealed that rimonabant significantly decreased shake consumption compared to vehicle treatment in both the home cage (1 mg/kg, p<0.001; 3 and 10 mg/kg, p<0.0001) and novel cage setting (1, 3, and 10 mg/kg, p<0.0001 for all). With respect to the effects of environmental context on shake consumption, post hoc Sidak's multiple comparisons test revealed a significant difference between home and novel condition for the rimonabant treatment group at 1 mg/kg (p=0.0002), but no significant difference for the other two doses of rimonabant (3 mg/kg, p=0.9978, NS; 10 mg/kg, p=0.9972, NS).
We also determined the effects of 1, 3, or 10 mg/kg rimonabant on the frequency and duration of shake consumption (drinking), grooming, and scratching during testing in either the home cage or novel cage setting. For the drinking frequency (Fig. 1c, left) , results revealed a significant effect of drug dose (F (3, 58) =10.75, p<0.0001), but no significant effect of testing condition (F (1, 58) =1.28, p=0.26, NS) or interaction (F (3, 58) =0.24, p=0.87, NS). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 1 mg/kg (p < 0.05 home cage; p < 0.01 novel cage), 3 mg/kg (p<0.05 for both), and 10 mg/kg (p<0.001 home cage; p<0.01 novel cage) significantly decreased drinking frequency compared to vehicle treatment in both the home and novel testing conditions. For the drinking duration (Fig. 1d, left) , results revealed a significant effect of drug dose (F (3, 58) = 20.05, p < 0.0001) and testing condition (F (1, 58) =10.59, p=0.0019), but no significant interaction (F (3, 58) =2.29, p=0.088, NS). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 1 mg/kg (p<0.05 home cage; p<0.001 novel cage), 3 mg/kg (p<0.0001 home cage; p<0.001 novel cage), and 10 mg/kg (p<0.0001 home cage; p<0.001 novel cage) significantly decreased drinking duration compared to vehicle treatment in both the home and novel testing conditions, respectively.
For grooming frequency (Fig. 1c, middle) , results revealed a significant effect of drug dose (F (3, 58) =15.83, p<0.0001), but no significant effect of testing condition (F (1, 58) =1.86, p=0.18, NS) or interaction (F (3,58) =0.26, p=0.85, NS). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 3 mg/kg (p<0.05 home cage; p<0.0001 novel cage) and 10 mg/kg (p<0.05 home cage; p<0.001 novel cage) significantly increased grooming frequency compared to vehicle treatment in both the home and novel testing conditions, respectively. For grooming duration (Fig. 1d, middle) , results revealed a significant effect of drug dose (F (3, 58) =9.27, p<0.0001), but no significant effect of testing condition (F (1, 58) =0.84, p=0.36, NS) or interaction (F (3, 58) =0.93, p=0.43, NS). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 10 mg/kg (p<0.01) in the home testing condition and rimonabant at 3 mg/kg (p<0.01) and 10 mg/kg (p<0.05) in the novel testing condition compared to vehicle treatment significantly increased grooming duration.
For scratching frequency (Fig. 1c, right) , results revealed a significant effect of drug dose (F (3, 58) =22.29, p<0.0001), but no significant effect of testing condition (F (1, 58) =0.067, p=0.80, NS) or interaction (F (3, 58) =1.52, p=0.22, NS). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 3 mg/kg (p<0.01 home cage; p<0.001 novel cage) and 10 mg/kg (p<0.001 home cage; p<0.0001 novel cage) significantly increased scratching frequency compared to vehicle treatment in both home and novel testing conditions, respectively. For scratching duration (Fig. 1d, right) , results revealed a significant effect of drug dose (F (3, 58) = 16.42, p<0.0001) and testing condition (F (1, 58) =21.04, p<0.0001), but no significant interaction (F (3, 58) =1.54, p=0.21). Post hoc Sidak's multiple comparisons test revealed that rimonabant at 3 mg/kg (p<0.001) and 10 mg/kg (p<0.0001) in the home testing condition and rimonabant at 10 mg/kg (p < 0.001) in the novel testing condition 
Effects of CB2 receptor blockade on NIH
We next tested the effects of the CB2 receptor antagonist/ inverse-agonist, SR144528, in the NIH assay in the novel cage setting since this condition yielded effects on both latency and consumption after CB1 receptor blockade (n=8-10/treatment group; data not shown). In contrast to the robust effects observed with rimonabant, one-way ANOVA did not reveal any effect of SR144528 at 1, 3, or 10 mg/kg on feeding latency (F (3, 32) =0.66, p=0.58, NS) or shake consumption (F (3, 32) =0.38, p=0.77, NS) in the novel cage setting.
Effects of CB1 receptor blockade on locomotor activity
Administration of the CB1 receptor antagonist rimonabant caused an increase in the horizontal activity counts (Fig. 2a) . Two-way repeated measures ANOVA factoring drug dose and time revealed a significant effect of drug dose (F (3, 44) =9.2, p<0.0001), time (F (5, 220) =89.0, p<0.0001), and dose X time interaction (F (15, 220) =5.68, p<0.0001). Post hoc Sidak's test revealed a significant increase in initial locomotor activity during the first 5 min (p<0.0001) and 10 min (p<0.05) bins of the assay at the 10-mg/kg dose of rimonabant compared to that of vehicle treatment. Ambulatory distance was also increased by rimonabant (one-way ANOVA: F (3, 44) =5.27, p=0.003; 10 mg/kg vs. vehicle, p<0.001 by Dunnett's post hoc test; Fig. 2b ). Rimonabant did not affect center time exploration (one-way ANOVA F (3, 44) =0.59, p=0.62, NS; Fig. 2c) or jump time or counts at any dose tested (data not shown).
Effects of CB1 receptor blockade on despair-like behavior Neither rimonabant at 3 nor 10 mg/kg affected duration of immobility over time (two-way ANOVA effect of drug dose F (2, 27) =0.27, p=0.76, NS) or total percentage immobility (one-way ANOVA F (2, 27) =0.30, p=0.74, NS) in the tail suspension test (data not shown).
Discussion
Here, we assessed the effects of acute pharmacological CB1 receptor blockade in the NIH test. CB1 receptor blockade with rimonabant robustly and dose-dependently decreased consumption of a palatable vanilla shake solution, time spent drinking, and the frequency of drinking bouts. This effect was not dependent upon the novelty/aversiveness of the environmental context, since similar effects were observed in animals tested in their familiar home cage or a mildly anxiogenic novel cage testing condition. In contrast, the effect of rimonabant to increase the latency to begin consuming the palatable solution was robustly increased only in the novel, anxiogenic environmental condition. These data highlight a clear dissociation between the anxiogenic-like effects of rimonabant, operationalized by an increase in feeding latency, and the antihedonic effects of rimonabant measured by total shake consumption and drinking time/frequency, with only the former showing environmental context dependence. Other common behaviors induced by rimonabant, including scratching and grooming, did not exhibit context dependence, with both behaviors being prominent in both home cage and novel cage environments. We also found no evidence that acute CB2 receptor blockade regulates either anxiety or consummatory behaviors in the NIH assay, and that the effects of rimonabant appear more selective for anxietylike behaviors relative to despair-like behaviors since no effects of acute CB1 receptor blockade were observed in the tail suspension test.
Over 15 years ago, seminal studies by Le Fur and coworkers demonstrated that administration of rimonabant decreased consumption of sucrose with little effect on nonpalatable food intake (Arnone et al. 1997) . Since then, many studies have demonstrated that rimonabant preferentially decreases consumption of palatable food over nonpalatable foods (Droste et al. 2010; Mathes et al. 2008; Poncelet et al. 2003; Thornton-Jones et al. 2005 , 2007 ; however, this is not a ubiquitous finding (Salamone et al. 2007; Verty et al. 2004) . It has been generally acknowledged that blockade of CB1 receptors decreases palatable food intake by decreasing the hedonic value of palatable foods, thereby decreasing the motivation to work for palatable rewards (Droste et al. 2010; Hernandez and Cheer 2012; Salamone et al. 2007 ). Importantly, rimonabant does not affect Pavlovian approach behaviors in an autoshaping paradigm (Thornton-Jones et al. 2005) . These data may be directly relevant to the present findings since the feeding latency in the home cage to some degree is driven by the Pavlovian approach behavior. Since latency times were unchanged by rimonabant treatment in the home cage, but shake consumption, drinking time, and drinking frequency were all dramatically reduced, our data generally support the hypothesis that CB1 receptor blockade decreased the hedonic value of palatable solution without affecting the initial expected value of the solution based on previous learning. The lack of rimonabant effect on feeding latency in the home cage argues against nonspecific behavioral suppression that has been suggested by some to account for the decrease in feeding behavior observed after CB1 receptor blockade. Specifically, Rodgers and co-workers have suggested that CB1 receptor blockade reduces feeding behavior by biasing behavioral repertoires toward groomingrelated behaviors (Tallett et al. 2007a, b) . If this were the case in our study, one would expect an increase in feeding latency to accompany the decrease in total consumption in the home cage. However, it could be argued that reduced consumption in the absence of changes in latency could still be due to interference of ongoing drinking behavior by grooming activity despite the initial approach time being unchanged in the home cage. Our subsequent analysis of grooming, scratching, and drinking time suggests that this is not the case, however. First, time spent grooming was similar in home and novel cage environments, indicating that grooming behavior did not interfere per se with the ability of mice to approach the sipper since latency times were very low in the home cage, yet grooming time was quite high. Secondly, although time spent grooming was similar between home and novel cage environments, total grooming time was only~33 % of total testing time at the highest dose of rimonabant, whereas drinking time was only~5.5 % of total testing time in the vehicle-treated mice. Therefore, it is unlikely that time spent grooming occupied sufficient testing time to reduce drinking time from~5.5 to~1.5 % in the 10 mg/kg rimonabant-treated mice. Even if time spent grooming and scratching are summed, this equals~44 % of total time, which again, is not likely sufficient to preclude drinking for~5.5 % of total testing time as seen in the control mice in the novel cage. These data suggest that rimonabant-induced anorectic effects are not mediated by behavioral competition with grooming and scratching behaviors. These findings are supported by recent data from Wright and co-workers showing that acute inhibition of food intake by rimonabant is not secondary to compulsive, stereotypic scratching and grooming behaviors in male rats (Wright and Rodgers 2012) .
Blockade of CB1 receptors is also known to increase anxiety-like behaviors in rodents (Navarro et al. 1997; Patel and Hillard 2006) ; however, some studies have demonstrated antianxiety effects also (Griebel et al. 2005) . Importantly, the anxiogenic effects of both acute pharmacological blockade and genetic CB1 receptor deletion have been shown to be dependent upon the environmental aversiveness of the testing conditions. Haller and co-workers demonstrated that aversive/stressful lighting conditions unmask anxiogeniclike behavioral effects in CB1 receptor knockout mice (Haller et al. 2004 ). In addition, we have demonstrated that the ability of rimonabant to increase plasma corticosterone is dependent upon stress exposure . Moreover, indirect CB1 receptor agonists decrease anxiety preferentially under high stress conditions (Naidu et al. 2007; Patel and Hillard 2006; Sciolino et al. 2011) . Taken together, these data strongly implicate a context-dependent role for endocannabinoids in the regulation of anxiety-like behaviors. Our findings are wholly consistent with this idea. We find that the increase in feeding latency, generally considered an anxiety-like measure (Dulawa and Hen 2005) , was only affected in the novel, stressful environment. The lack of effect on latency in the home cage also rules out nonspecific motor deficits as contributing to these results, as do the generally small effects of rimonabant on motor activity observed in the open-field motor assay. Specifically, an increase in feeding latency could potentially be due to locomotor suppressant effects of the drug treatment as suggested by Jarbe et al. (2006) ; however, we found an increase in locomotor activity after the highest dose of rimonabant ruling out this possibility. This increase in locomotion seen after the 10-mg/kg rimonabant dose may be due to enhanced dopamine receptor function as previously suggested (Fernandez-Espejo et al. 2005; Giuffrida et al. 1999) . Surprisingly, we did not observe a clear anxiogenic effect in the open-field assay with any dose of rimonabant. Given the above discussion of the context dependency of rimonabant-induced anxiogenesis, one possible explanation for a lack of effect could be that the environment of the open-field assay was not aversive enough. Taken together with the consumption data, our findings highlight for the first time a clear dissociation of the context dependence of the effects of rimonabant on anxiety-like and consummatory behaviors, with only anxiety being affected by environmental aversiveness.
Another interesting finding that emerged from our data is the differential sensitivity of various behaviors to CB1 receptor blockade. While the rimonabant-induced anorectic effects appear at the lowest dose, the anxiogenic effect of rimonabant was intermediately sensitive at the 3 mg/kg dose, and rimonabant-induced hyperactivity was only seen at the highest dose. In addition to the differential context dependency of these behaviors, the differential dose dependency further suggests that these behavioral effects are mediated via distinct and partially dissociable neural mechanisms. We speculate that this differential dose sensitivity could be related to the level of eCB tone within distinct neural circuits/synapses that regulate these distinct behavioral responses. Specifically, we suggest that neural circuits regulating hedonic processes have the highest level of tonic eCB signaling and, thus, are most sensitive to CB1 receptor blockade. In contrast, locomotor pathways including corticostriatal circuits would have the lowest level of regulation by tonic eCB signaling and, therefore, only be affected by very high levels of CB1 blockade.
Our data also provide two additional levels of specificity to our findings. First, acute blockade of CB2 receptor had no effect on NIH at any dose tested. This is not altogether surprising given the very low expression of CB2 receptors in the brain under basal conditions (Griffin et al. 1999; Nunez et al. 2004; Onaivi et al. 2006) . Secondly, we show that CB1 receptor blockade at the same doses that robustly affect NIH do not affect despair-like behavior in the tail suspension test. These data are surprising in light of the positive effects of pharmacological CB1 receptor blockade on despair-like behavior previously published (Griebel et al. 2005; Shearman et al. 2003; Tzavara et al. 2003) ; however, given the propensity of rimonabant to increase anxiety and depressive symptoms in some humans (Christensen et al. 2007 ), interpretation of these positive results remains difficult (but see Haring et al. 2013 for possible explanations).
In conclusion, our data provide evidence for the dissociation of the context dependence of CB1 receptor blockadeinduced anxiety-like and anorectic effects. We confirm that anxiety-like responses induced by CB1 receptor blockade are exaggerated under conditions of high environmental aversiveness, and that acute CB2 receptor blockade has no effect on either anxiety or appetitive consummatory behaviors in the NIH assay. These data suggest that CB1 receptor blockade affects dissociable neural processes underlying the generation of anxiety and anorexia to sculpt complex and context-dependent behavioral repertoires.
